Plain-English translation of NCT03786796 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether , a medication that targets defects in DNA repair genes, can help people with advanced kidney cancer that has spread to other parts of the body. You would only qualify if genetic testing shows your cancer cells have specific mutations in DNA repair genes. The medication works differently than many standard kidney cancer treatments, so researchers want to see if it helps people whose cancer has continued to grow despite prior therapies.
Many people with advanced kidney cancer eventually stop responding to standard treatments like immunotherapy or anti-angiogenic drugs. This study exists to find out if this medication, which targets a different weakness in cancer cells, might work for patients with specific genetic mutations whose cancer has already progressed.
You likely qualify if…
You likely don't qualify if…
You would start taking the medication twice daily by mouth, beginning at a lower dose for one month, then increasing to a higher dose if you tolerate it well. You would visit the clinic at least once a month for blood work and side effect checks, and have imaging scans (like CT scans) every three months to see how your cancer is responding. Treatment continues as long as the medication is helping and side effects remain manageable, which could be several months or longer.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
United States